Levels: Who It's Best For and Ideal Patient Profile

What Levels Actually Does

Levels is a subscription service that ships an FDA-cleared continuous glucose monitor to your door, then layers proprietary software on top of the raw glucose data. The software assigns a "Metabolic Score" to meals, workouts, and sleep periods based on how your blood sugar responds. It is a behavior-feedback loop, not a medical device in itself.

The CGM hardware (typically an Abbott FreeStyle Libre 2 or 3 sensor) measures interstitial glucose every 1 to 5 minutes. Levels aggregates this stream and applies algorithms that penalize glucose spikes above a user-set threshold, prolonged elevations, and high glycemic variability. A 2023 study published in the Journal of Clinical Endocrinology & Metabolism found that real-time CGM feedback reduced time spent above 140 mg/dL by 27% in non-diabetic adults over 10 days (1). The concept is sound. Whether Levels specifically outperforms a standalone CGM with free logging apps is a different question.

The company does not prescribe medications. It does not diagnose diabetes. It gives you a mirror for your glucose patterns and a scoring system designed to nudge dietary choices. That distinction matters for understanding who should and should not sign up.

The Ideal Patient Profile for Levels

Adults most likely to extract value from Levels share a few common traits: they are metabolically at risk but not yet on insulin, they respond to quantified feedback, and they can afford an out-of-pocket wellness subscription. The tool is not designed for type 1 diabetes management or acute glycemic emergencies.

Prediabetes. The CDC estimates 98 million U.S. adults have prediabetes, and 80% of them do not know it (2). For this group, seeing a real-time glucose spike after a bowl of white rice can be more motivating than a yearly fasting glucose lab. A randomized trial by Ehrhardt et al. (2019, N=100) demonstrated that CGM use in prediabetic adults led to a 0.3% reduction in HbA1c over 3 months compared to standard dietary counseling alone (3).

Insulin resistance and PCOS. Women with polycystic ovary syndrome frequently exhibit insulin resistance that standard labs may underdetect. The Endocrine Society's 2023 clinical practice guideline on PCOS recommends screening for dysglycemia using oral glucose tolerance testing (4). CGM adds a layer of granularity by revealing postprandial patterns that a single fasting glucose cannot capture.

Weight-management patients on GLP-1 therapy. Patients taking semaglutide or tirzepatide may benefit from CGM data that confirms their improved glycemic control and reinforces dietary changes. In the SURMOUNT-1 trial (N=2,539), tirzepatide 15 mg reduced HbA1c by 0.5% even in non-diabetic participants (5). Pairing this pharmacologic effect with CGM visualization could strengthen adherence, though no published RCT has tested this combination with Levels specifically.

Biohackers and quantified-self enthusiasts. This is the original Levels audience. Healthy adults with normal glucose tolerance who want to experiment with meal timing, macronutrient ratios, and exercise sequencing. The clinical benefit here is less clear. A 2024 systematic review in Diabetes Technology & Therapeutics concluded that CGM in normoglycemic adults produces "minimal actionable data beyond confirming normal glucose homeostasis" (6).

Who Should Skip Levels

Not every person curious about metabolic health needs a CGM subscription. The tool has real limitations, and for some groups the cost-benefit math does not work.

Type 1 diabetes patients. Levels is not built for insulin dosing decisions. Type 1 patients need integrated CGM-insulin pump systems or at minimum a CGM paired with a certified diabetes educator. The American Diabetes Association's 2024 Standards of Care explicitly recommend CGM systems with alarm functions and insulin dose calculators for type 1 management (7). Levels does not offer these features.

Type 2 patients on insulin. Similar reasoning applies. If you are titrating basal insulin, you need clinical-grade CGM integration, not a wellness score.

People seeking a diagnosis. A Levels subscription cannot diagnose diabetes or prediabetes. An HbA1c or oral glucose tolerance test ordered through a licensed provider remains the diagnostic standard. The CGM data may prompt you to seek formal testing, but it does not replace it.

Budget-conscious patients. At roughly $199 to $399 per month, Levels is a premium wellness product. For comparison, a basic FreeStyle Libre 3 sensor costs approximately $75 per month at retail without insurance. If you do not need the scoring algorithm and coaching content, the raw sensor plus a free app like LibreLinkUp may deliver 80% of the benefit at a fraction of the price.

Is Levels Legit? Evaluating the Evidence

The company is legitimate in the sense that it ships real FDA-cleared CGM hardware, employs licensed physicians who write prescriptions, and operates within telehealth regulations. It is not a scam. The deeper question is whether the proprietary software layer provides clinical value above the CGM hardware alone.

Levels has published internal data and funded pilot studies, but as of May 2026, no independent, peer-reviewed randomized controlled trial has evaluated the Levels platform specifically against a control group. This is a gap. The underlying CGM technology has strong evidence. A 2018 study in PLOS Biology showed that even normoglycemic individuals classified as "healthy" by standard criteria exhibited glucose spikes into the prediabetic and diabetic range during continuous monitoring (8). That finding supports the concept, but it does not validate Levels' proprietary scoring algorithm.

Dr. Robert Lustig, a pediatric endocrinologist at UCSF, has stated: "Continuous glucose monitoring gives people agency over their metabolic health in ways that annual lab work simply cannot. The question is whether that data translates into sustained behavior change" (9). That question remains partially unanswered for wellness-oriented CGM programs.

The company holds a B-corporation certification, has raised over $100 million in venture funding, and employs physicians and registered dietitians on staff. Its advisory board includes published researchers. Legitimacy is not the concern. Proving superiority over cheaper CGM access pathways is the outstanding challenge.

Levels vs. Alternatives

Several competitors now occupy the non-diabetic CGM market. Comparing them requires looking at hardware, software, clinical support, and price.

Levels vs. Nutrisense. Nutrisense pairs CGM sensors with access to a registered dietitian for personalized coaching. Plans start around $225 per month. The key difference: Nutrisense emphasizes one-on-one dietitian interaction, while Levels emphasizes software-driven scores and self-guided learning. For patients who want human accountability, Nutrisense may be the better fit. For tech-oriented users who prefer app-driven feedback, Levels has the edge.

Levels vs. January AI. January AI uses CGM data combined with AI-powered meal predictions. It claims to predict glucose responses before you eat, using machine learning trained on prior meal data. A 2021 feasibility study showed that meal-prediction algorithms can achieve roughly 85% accuracy in forecasting postprandial glucose peaks in controlled settings (10). January AI's predictive approach is conceptually distinct from Levels' reactive scoring.

Levels vs. standalone CGM. The most cost-effective option for many users. Abbott's FreeStyle Libre 3 sensor, paired with the free LibreLink app, provides raw glucose data and trend arrows. You lose the metabolic score, curated content library, and structured program. You gain simplicity and savings of $100+ per month. A 2022 analysis in Diabetes Care found that CGM adherence dropped significantly after 3 months in non-diabetic users regardless of platform (11). This suggests that the novelty factor, not the specific platform, drives initial engagement.

What Does a Typical Levels Experience Look Like?

Understanding the user journey helps set expectations. Levels is not a one-time purchase. It is a structured program.

Month 1: Discovery phase. You receive your CGM sensor kit, apply the sensor to the back of your upper arm, and begin logging meals through the app. The first two weeks are a calibration period where the algorithm learns your baseline patterns. Most users report 5 to 10 "surprise" findings in their first month, such as discovering that their morning oatmeal spikes glucose higher than expected.

Month 2: Optimization. Armed with baseline data, users begin experimenting. Common interventions include reordering macronutrients (eating protein before carbohydrates), adding post-meal walks, and testing individual food swaps. A 2015 landmark study in Cell (N=800) demonstrated that glycemic responses to identical foods vary enormously between individuals, with some participants spiking after bananas but not cookies, and vice versa (12). This personalized variability is exactly what Levels aims to capture.

Month 3 and beyond: Maintenance or exit. Many users find diminishing returns after 2 to 3 months. The major dietary lessons have been learned, and continuous monitoring becomes less necessary. Levels offers ongoing subscriptions for users who want persistent tracking, but the company has acknowledged that many members cycle on and off rather than maintaining continuous use. This is an honest signal. If the product provided irreplaceable ongoing value, churn would be lower.

Cost Breakdown and Insurance Reality

Levels does not accept insurance. This is a direct-to-consumer wellness product, not a covered medical benefit. The pricing structure has shifted since launch but generally falls into tiered plans.

The base annual membership runs approximately $199 per year, which covers app access and content. CGM sensors are purchased separately or bundled, typically adding $150 to $200 per month for two sensors (each lasting 14 days). Total out-of-pocket for a 3-month program ranges from roughly $650 to $1,000 depending on the plan selected.

For comparison, patients with a prediabetes diagnosis may qualify for insurance-covered CGM through traditional prescribing pathways. The ADA's 2024 Standards of Care support CGM use for patients with type 2 diabetes on intensive insulin therapy (7), but coverage for prediabetes or metabolic wellness remains rare. Some HSA and FSA accounts will reimburse CGM purchases with a physician's letter of medical necessity, and Levels provides documentation to support these claims.

The Clinical Case for CGM in Non-Diabetic Populations

The science behind using CGMs outside of diabetes management is growing but not yet definitive. Several key findings support the concept.

Glucose variability, independent of average glucose, correlates with cardiovascular risk markers. A 2019 study in Cardiovascular Diabetology (N=1,765) found that higher glycemic variability measured by MAGE (mean amplitude of glycemic excursion) was independently associated with increased carotid intima-media thickness (13). This suggests that even in non-diabetic individuals, flattening glucose spikes may have vascular benefits.

Postprandial hyperglycemia above 140 mg/dL has been associated with increased oxidative stress and endothelial dysfunction in non-diabetic adults according to research published in the European Heart Journal (14). The International Diabetes Federation's guideline on postmeal glucose management recommends that two-hour postprandial glucose should not exceed 140 mg/dL, even in non-diabetic individuals (15).

These data points provide a physiologic rationale for monitoring glucose in non-diabetic populations. They do not prove that using a CGM to reduce spikes will prevent cardiovascular events. That trial has not been done. The mechanism is plausible, the outcomes data are missing.

Levels Reviews: What Real Users Report

Aggregated user reviews across Trustpilot, Reddit, and app store listings reveal consistent themes. Users frequently praise the "aha moment" of seeing glucose responses in real time. Meal scoring is cited as the single most useful feature. The most common complaint is cost, followed by sensor adhesion issues (a hardware limitation, not specific to Levels).

A recurring criticism from clinicians is that Levels may provoke unnecessary anxiety in metabolically healthy users. Seeing glucose fluctuations that are physiologically normal (e.g., a post-meal rise to 150 mg/dL that returns to baseline within 90 minutes) can trigger restrictive eating behaviors in susceptible individuals. Dr. Anne Peters, professor of clinical medicine at USC Keck School of Medicine, has cautioned: "In the wrong patient, a CGM can become an instrument of orthorexia rather than a tool for metabolic insight" (16).

This concern is worth weighing. Levels does include educational content framing normal glucose variability, but the scoring system inherently penalizes any spike, which could reinforce overly rigid dietary thinking in certain personality types.

The median user rating across platforms sits around 4.1 out of 5 stars, with the highest satisfaction among users who had a specific metabolic goal (weight loss, prediabetes reversal) and the lowest among those who signed up out of general curiosity without a defined objective.